One day we hope to be able to say — well, here’s a disease, and then click a button and out pops the design for a drug to ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

Investing in attractive dividend growth stocks can lead to superior long-term returns. The two healthcare companies below ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Eli Lilly and Company (NYSE: LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...

Wall Street analysts remain bullish on Eli Lilly, boasting an Average Brokerage Recommendation (ABR) of 1.46, largely between ...

The Howard County Board of Education is suing several Big Pharma companies for allegedly inflating insulin prices, affecting ...

Linear relationship seen for waist circumference, BP; reduction in HOMA-IR, hemoglobin A1c seen with modest weight reduction.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...